8月19日，赛诺医疗今日收盘40.42元，下跌2.56%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到2738.89倍，总市值168.17亿元。 来源：金融界 赛诺医疗科学技术股份有限公司的主营业务是高端介入医疗器械研发、生产、销售。公司的主要产品是 生物降解药物涂层冠脉支架系统、药物洗脱支架系统、非顺应性PTCA球囊扩张导管、PTCA球囊扩张 导管、非顺应性球囊扩张导管、冠脉球囊扩张导管、冠状动脉棘突球囊扩张导管、延长导管、颅内药物 洗脱支架系统、颅内取栓支架、颅内球囊扩张导管、负压吸引泵、一次性使用无菌吸引延长管、远端通 路导管、颅内血栓抽吸导管、微导管、远端通路导引导管、导引导管、桡动脉通路导引系统、输送导 管、球囊导引导管。 最新一期业绩显示，2025年一季报，公司实现营业收入1.01亿元，同比10.75%；净利润296.93万元，同 比277.50%，销售毛利率59.66%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13赛诺医疗2738.8911227.6219.32168.17亿行业平均 59.4955.005.10121.17亿行业中值40.1939.642.955 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Sainuo Medical, indicating a significant increase in net profit and a high PE ratio compared to industry averages [1][2] - As of March 31, 2025, Sainuo Medical had 11,044 shareholders, an increase of 381 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, production, and sales of high-end interventional medical devices, with key products including biodegradable drug-coated coronary stent systems and various types of balloon dilation catheters [1] Group 2 - In the first quarter of 2025, Sainuo Medical reported revenue of 101 million yuan, a year-on-year increase of 10.75%, and a net profit of 2.9693 million yuan, reflecting a substantial year-on-year growth of 277.50% [2] - The company's gross profit margin stood at 59.66%, indicating strong profitability relative to its revenue [2] - Sainuo Medical's rolling PE ratio is 850.40, significantly higher than the industry average of 53.52 and the median of 37.14, positioning it at 121st in the industry ranking [2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Sino Medical, noting its significant increase in stock price and high PE ratio compared to industry averages [1][2] - As of July 18, Sino Medical's stock closed at 12.12 yuan, up 7.73%, with a rolling PE ratio of 821.26, marking a new low in 285 days and a total market capitalization of 5.043 billion yuan [1] - The average PE ratio for the medical device industry is 52.34, with a median of 36.99, placing Sino Medical at the 121st position in the industry ranking [1][2] Group 2 - For Q1 2025, Sino Medical reported revenue of 101 million yuan, a year-on-year increase of 10.75%, and a net profit of 2.9693 million yuan, reflecting a substantial year-on-year growth of 277.50% [2] - The company's gross profit margin stands at 59.66%, indicating strong profitability relative to its revenue [2] - As of March 31, 2025, Sino Medical had 11,044 shareholders, an increase of 381 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

Core Viewpoint - Sino Medical reported a closing price of 10.69 yuan, down 1.75%, with a rolling PE ratio of 724.36 times, and a total market value of 4.448 billion yuan [1] Company Summary - Sino Medical's main business focuses on the research, development, production, and sales of high-end interventional medical devices [1] - Key products include biodegradable drug-coated coronary stent systems, drug-eluting stent systems, non-compliant PTCA balloon dilatation catheters, and various other specialized medical devices [1] Financial Performance - For Q1 2025, the company achieved an operating income of 101 million yuan, representing a year-on-year increase of 10.75% [2] - The net profit for the same period was 2.9693 million yuan, showing a significant year-on-year increase of 277.50% [2] - The sales gross margin stood at 59.66% [2] Industry Comparison - The average PE ratio for the medical device industry is 49.45 times, with a median of 35.92 times, positioning Sino Medical at 121st place within the industry [1] - The company's static PE ratio is 296.94 times, and the price-to-book ratio is 5.11 [2]